Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Colon Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 35 active trials
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Oxaliplatin | Approved | Phase 3 | 13 | 5 | 15 | 51 | 2 | US | Aug 7, 2009 | 1999-11 |
| Fluorouracil | Approved | Phase 4 | 8 | 4 | 18 | 51 | 1 | US | Feb 20, 2026 | 1993-11 |
| Capecitabine | Approved | Phase 3 | 7 | 4 | 7 | 29 | 1 | US | Apr 30, 1998 | 2002-02 |
| Irinotecan | Approved | Phase 3 | 4 | 2 | 6 | 35 | 4 | US | Jun 14, 1996 | 1999-05 |
| Bevacizumab | Approved | Phase 3 | 3 | 2 | 9 | 32 | 1 | US | Feb 26, 2004 | 2001-09 |
| Tegafur | Phase 4 | Phase 4 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-09 |
| Nivolumab | Phase 3 | Phase 3 | 7 | 2 | 1 | 13 | 0 | — | — | Aug 17, 2015 |
| Cetuximab | Phase 3 | Phase 3 | 6 | 1 | 4 | 32 | 0 | — | — | 2003-12 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 4 | 1 | 2 | 6 | 0 | — | — | 2014-10 |
| Leucovorin | Phase 3 | Phase 3 | 3 | 0 | 14 | 42 | 0 | — | — | 1993-11 |
| CAPOX Regimen | Phase 3 | Phase 3 | 3 | 2 | 1 | 6 | 0 | — | — | Jun 16, 2020 |
| Fruquintinib | Phase 3 | Phase 3 | 3 | 1 | 1 | 5 | 0 | — | — | Dec 11, 2017 |
| Encorafenib | Phase 3 | Phase 3 | 3 | 0 | 1 | 4 | 0 | — | — | Jun 14, 2019 |
| Panitumumab | Phase 3 | Phase 3 | 2 | 1 | 2 | 15 | 0 | — | — | 2004-12 |
| Aspirin | Phase 3 | Phase 3 | 2 | 0 | 3 | 6 | 0 | — | — | 2007-03 |
| Ipilimumab | Phase 3 | Phase 3 | 2 | 2 | 1 | 6 | 0 | — | — | 2013-02 |
| Trastuzumab | Phase 3 | Phase 3 | 2 | 1 | 1 | 5 | 0 | — | — | Aug 17, 2015 |
| Pertuzumab | Phase 3 | Phase 3 | 2 | 1 | 1 | 4 | 0 | — | — | 2007-10 |
| Atezolizumab | Phase 3 | Phase 3 | 2 | 1 | 2 | 2 | 0 | — | — | Oct 16, 2017 |
| FOLFOX Regimen | Phase 3 | Phase 3 | 1 | 1 | 2 | 6 | 0 | — | — | 2004-12 |
| Celecoxib | Phase 3 | Phase 3 | 1 | 1 | 1 | 5 | 0 | — | — | 2000-03 |
| Temozolomide | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Jan 15, 2019 |
| Immunomodulatory Oligonucleotide | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Apr 15, 2026 |
| Levoleucovorin | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2002-10 |
| Pegfilgrastim | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Feb 1, 2003 |
| Avelumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Aug 31, 2018 |
| Chemotherapy | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Nov 3, 2009 |
| Pembrolizumab | Phase 2 | Phase 2 | 5 | 1 | 0 | 10 | 0 | — | — | Jun 14, 2016 |
| Sintilimab | Phase 2 | Phase 2 | 3 | 2 | 0 | 3 | 0 | — | — | 2024-11 |
| Cyclophosphamide | Phase 2 | Phase 2 | 2 | 2 | 0 | 6 | 0 | — | — | Sep 21, 2017 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 2000-07 |
| Fludarabine | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | Sep 21, 2017 |
| Dostarlimab | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Mar 24, 2023 |
| Zanidatamab | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Feb 15, 2023 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 9 | 0 | — | — | 2004-12 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2007-07 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2009-10 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Feb 11, 2022 |
| Everolimus | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2008-11 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Tucatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Feb 15, 2023 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 4, 2016 |
| Dexamethasone | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2002-02 |
| Serplulimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 1, 2023 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | May 15, 2020 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 4, 2020 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 23, 2021 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.